Literature DB >> 30301860

Renal COP9 Signalosome Deficiency Alters CUL3-KLHL3-WNK Signaling Pathway.

Ryan J Cornelius1, Jinge Si1, Catherina A Cuevas1, Jonathan W Nelson1, Brittany D K Gratreak1, Ruggero Pardi2, Chao-Ling Yang1, David H Ellison3,4.   

Abstract

BACKGROUND: The familial hyperkalemic hypertension (FHHt) cullin 3 (CUL3) mutant does not degrade WNK kinases normally, thereby leading to thiazide-sensitive Na-Cl cotransporter (NCC) activation. CUL3 mutant (CUL3Δ9) does not bind normally to the COP9 signalosome (CSN), a deneddylase involved in regulating cullin-RING ligases. CUL3Δ9 also caused increased degradation of the CUL3-WNK substrate adaptor kelch-like 3 (KLHL3). Here, we sought to determine how defective CSN action contributes to the CUL3Δ9 phenotype.
METHODS: The Pax8/LC1 mouse system was used to generate mice in which the catalytically active CSN subunit, Jab1, was deleted only along the nephron, after full development (KS-Jab1 -/-).
RESULTS: Western blot analysis demonstrated that Jab1 deletion increased the abundance of neddylated CUL3. Moreover, total CUL3 expression was reduced, suggesting decreased CUL3 stability. KLHL3 was almost completely absent in KS-Jab1 -/- mice. Conversely, the protein abundances of WNK1, WNK4, and SPAK kinases were substantially higher. Activation of WNK4, SPAK, and OSR1 was indicated by higher phosphorylated protein levels and translocation of the proteins into puncta, as observed by immunofluorescence. The ratio of phosphorylated NCC to total NCC was also higher. Surprisingly, NCC protein abundance was low, likely contributing to hypokalemia and Na+ and K+ wasting. Additionally, long-term Jab1 deletion resulted in kidney damage.
CONCLUSIONS: Together, the results indicate that deficient CSN binding contributes importantly to the FHHt phenotype. Although defective CUL3Δ9-faciliated WNK4 degradation likely contributes, dominant effects on KLHL3 may be a second factor that is necessary for the phenotype.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Cell & Transport Physiology; Na transport; distal tubule; renal hypertension

Mesh:

Substances:

Year:  2018        PMID: 30301860      PMCID: PMC6218864          DOI: 10.1681/ASN.2018030333

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  54 in total

1.  The WNK1 and WNK4 protein kinases that are mutated in Gordon's hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases.

Authors:  Alberto C Vitari; Maria Deak; Nick A Morrice; Dario R Alessi
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

2.  Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice.

Authors:  Huabo Su; Jie Li; Suchithra Menon; Jinbao Liu; Asangi R Kumarapeli; Ning Wei; Xuejun Wang
Journal:  Circ Res       Date:  2010-11-04       Impact factor: 17.367

3.  Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density.

Authors:  Haim Mayan; Iris Vered; Meir Mouallem; Michal Tzadok-Witkon; Rachel Pauzner; Zvi Farfel
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 4.  The COP9 signalosome.

Authors:  Ning Wei; Xing Wang Deng
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

5.  SPAK differentially mediates vasopressin effects on sodium cotransporters.

Authors:  Turgay Saritas; Aljona Borschewski; James A McCormick; Alexander Paliege; Christin Dathe; Shinichi Uchida; Andrew Terker; Nina Himmerkus; Markus Bleich; Sylvie Demaretz; Kamel Laghmani; Eric Delpire; David H Ellison; Sebastian Bachmann; Kerim Mutig
Journal:  J Am Soc Nephrol       Date:  2013-02-07       Impact factor: 10.121

6.  Impaired degradation of WNK1 and WNK4 kinases causes PHAII in mutant KLHL3 knock-in mice.

Authors:  Koichiro Susa; Eisei Sohara; Tatemitsu Rai; Moko Zeniya; Yutaro Mori; Takayasu Mori; Motoko Chiga; Naohiro Nomura; Hidenori Nishida; Daiei Takahashi; Kiyoshi Isobe; Yuichi Inoue; Kenta Takeishi; Naoki Takeda; Sei Sasaki; Shinichi Uchida
Journal:  Hum Mol Genet       Date:  2014-05-12       Impact factor: 6.150

Review 7.  Nedd8 on cullin: building an expressway to protein destruction.

Authors:  Zhen-Qiang Pan; Alex Kentsis; Dora C Dias; Kosj Yamoah; Kenneth Wu
Journal:  Oncogene       Date:  2004-03-15       Impact factor: 9.867

8.  Mutant Cullin 3 causes familial hyperkalemic hypertension via dominant effects.

Authors:  Mohammed Z Ferdaus; Lauren N Miller; Larry N Agbor; Turgay Saritas; Jeffrey D Singer; Curt D Sigmund; James A McCormick
Journal:  JCI Insight       Date:  2017-12-21

9.  Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo.

Authors:  Michelle O'Reilly; Elaine Marshall; Thomas Macgillivray; Manish Mittal; Wei Xue; Chris J Kenyon; Roger W Brown
Journal:  J Am Soc Nephrol       Date:  2006-08-09       Impact factor: 10.121

10.  Targeted inhibition of the COP9 signalosome for treatment of cancer.

Authors:  Anita Schlierf; Eva Altmann; Jean Quancard; Anne B Jefferson; René Assenberg; Martin Renatus; Matthew Jones; Ulrich Hassiepen; Michael Schaefer; Michael Kiffe; Andreas Weiss; Christian Wiesmann; Richard Sedrani; Jörg Eder; Bruno Martoglio
Journal:  Nat Commun       Date:  2016-10-24       Impact factor: 14.919

View more
  11 in total

Review 1.  Hypertension-causing cullin 3 mutations disrupt COP9 signalosome binding.

Authors:  Ryan J Cornelius; Chao-Ling Yang; David H Ellison
Journal:  Am J Physiol Renal Physiol       Date:  2019-12-09

Review 2.  Kelch-like protein 3 in human disease and therapy.

Authors:  Yan Lin; Qian Li; Xiaofeng Jin
Journal:  Mol Biol Rep       Date:  2022-05-18       Impact factor: 2.742

3.  COP9 signalosome deletion promotes renal injury and distal convoluted tubule remodeling.

Authors:  Ryan J Cornelius; Jonathan W Nelson; Xiao-Tong Su; Chao-Ling Yang; David H Ellison
Journal:  Am J Physiol Renal Physiol       Date:  2022-05-09

Review 4.  Cullin-3: Renal and Vascular Mechanisms Regulating Blood Pressure.

Authors:  Jing Wu; James A McCormick; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2020-08-27       Impact factor: 5.369

Review 5.  Cullin-Ring ubiquitin ligases in kidney health and disease.

Authors:  Ryan J Cornelius; Mohammed Z Ferdaus; Jonathan W Nelson; James A McCormick
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-09       Impact factor: 2.894

6.  Decreased KLHL3 expression is involved in the activation of WNK-OSR1/SPAK-NCC cascade in type 1 diabetic mice.

Authors:  Qin Guo; Ya Zhang; Geng-Ru Jiang; Chong Zhang
Journal:  Pflugers Arch       Date:  2021-01-11       Impact factor: 3.657

7.  Novel CUL3 Variant Causing Familial Hyperkalemic Hypertension Impairs Regulation and Function of Ubiquitin Ligase Activity.

Authors:  Harish E Chatrathi; Jason C Collins; Lynne A Wolfe; Thomas C Markello; David R Adams; William A Gahl; Achim Werner; Prashant Sharma
Journal:  Hypertension       Date:  2021-12-02       Impact factor: 10.190

8.  Combined Kelch-like 3 and Cullin 3 Degradation is a Central Mechanism in Familial Hyperkalemic Hypertension in Mice.

Authors:  Yujiro Maeoka; Mohammed Z Ferdaus; Ryan J Cornelius; Avika Sharma; Xiao-Tong Su; Lauren N Miller; Joshua A Robertson; Susan B Gurley; Chao-Ling Yang; David H Ellison; James A McCormick
Journal:  J Am Soc Nephrol       Date:  2022-01-21       Impact factor: 14.978

9.  Control of Podocyte and Glomerular Capillary Wall Structure and Elasticity by WNK1 Kinase.

Authors:  Zhenan Liu; Joonho Yoon; Chonlarat Wichaidit; Ankita B Jaykumar; Hashem A Dbouk; Addie E Embry; Liping Liu; Joel M Henderson; Audrey N Chang; Melanie H Cobb; Richard Tyler Miller
Journal:  Front Cell Dev Biol       Date:  2021-02-02

Review 10.  Role of the Ubiquitin Proteasome System in the Regulation of Blood Pressure: A Review.

Authors:  Osamu Yamazaki; Daigoro Hirohama; Kenichi Ishizawa; Shigeru Shibata
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.